Literature DB >> 21278773

Head and neck cancer in 2010: Maximizing survival and minimizing toxicity.

Bruce E Brockstein1, Everett E Vokes.   

Abstract

Outcomes for patients with oropharyngeal cancer are determined by their tumor characteristics and associated demographics. The role of human papilloma virus-related disease for prognosis and outcomes with chemoradiotherapy is being more clearly defined. EGFR inhibitors are used in conjunction with radiotherapy, and the importance of optimizing radiation quality and minimizing toxicity is the focus of ongoing studies.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21278773     DOI： 10.1038/nrclinonc.2010.226

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  8 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

2.  Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.

Authors:  Lester J Peters; Brian O'Sullivan; Jordi Giralt; Thomas J Fitzgerald; Andy Trotti; Jacques Bernier; Jean Bourhis; Kally Yuen; Richard Fisher; Danny Rischin
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

3.  Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results.

Authors:  Felix Y Feng; Hyungjin M Kim; Teresa H Lyden; Marc J Haxer; Francis P Worden; Mary Feng; Jeffrey S Moyer; Mark E Prince; Thomas E Carey; Gregory T Wolf; Carol R Bradford; Douglas B Chepeha; Avraham Eisbruch
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

4.  Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.

Authors:  Ezra E W Cohen; Daniel J Haraf; Rangesh Kunnavakkam; Kerstin M Stenson; Elizabeth A Blair; Bruce Brockstein; Eric P Lester; Joseph K Salama; Allison Dekker; Rosalyn Williams; Mary Ellyn Witt; Tatyana A Grushko; James J Dignam; Mark W Lingen; Olufunmilayo I Olopade; Everett E Vokes
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

5.  Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.

Authors:  Danny Rischin; Richard J Young; Richard Fisher; Stephen B Fox; Quynh-Thu Le; Lester J Peters; Ben Solomon; Jimin Choi; Brian O'Sullivan; Lizbeth M Kenny; Grant A McArthur
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

6.  Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.

Authors:  J K Salama; K M Stenson; E O Kistner; B B Mittal; A Argiris; M E Witt; F Rosen; B E Brockstein; E E W Cohen; D J Haraf; E E Vokes
Journal:  Ann Oncol       Date:  2008-06-06       Impact factor: 32.976

7.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Roger B Cohen; Christopher U Jones; Ranjan K Sur; David Raben; Jose Baselga; Sharon A Spencer; Junming Zhu; Hagop Youssoufian; Eric K Rowinsky; K Kian Ang
Journal:  Lancet Oncol       Date:  2009-11-10       Impact factor: 41.316

8.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245
  8 in total
  12 in total

1.  Implications of the oropharyngeal cancer epidemic.

Authors:  Edmund A Mroz; Arlene A Forastiere; James W Rocco
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

2.  Sparing the region of the salivary gland containing stem cells preserves saliva production after radiotherapy for head and neck cancer.

Authors:  Peter van Luijk; Sarah Pringle; Joseph O Deasy; Vitali V Moiseenko; Hette Faber; Allan Hovan; Mirjam Baanstra; Hans P van der Laan; Roel G J Kierkels; Arjen van der Schaaf; Max J Witjes; Jacobus M Schippers; Sytze Brandenburg; Johannes A Langendijk; Jonn Wu; Robert P Coppes
Journal:  Sci Transl Med       Date:  2015-09-16       Impact factor: 17.956

3.  Immunometabolic Alterations by HPV Infection: New Dimensions to Head and Neck Cancer Disparity.

Authors:  Sanjib Chaudhary; Koelina Ganguly; Sakthivel Muniyan; Ramesh Pothuraju; Zafar Sayed; Dwight T Jones; Surinder K Batra; Muzafar A Macha
Journal:  J Natl Cancer Inst       Date:  2019-03-01       Impact factor: 13.506

4.  Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma.

Authors:  Theresa L Whiteside; Robert L Ferris; Miroslaw Szczepanski; Mitchell Tublin; Joseph Kiss; Rita Johnson; Jonas T Johnson
Journal:  Head Neck       Date:  2015-07-15       Impact factor: 3.147

5.  Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Bastian Schilling; Zenichiro Saze; Laura Strauss; Stephan Lang; Jonas T Johnson; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

6.  Gene Expression Characterization of HPV Positive Head and Neck Cancer to Predict Response to Chemoradiation.

Authors:  Bryan J Thibodeau; Timothy J Geddes; Laura E Fortier; Samreen Ahmed; Barbara L Pruetz; Jessica Wobb; Peter Chen; George D Wilson; Jan A Akervall
Journal:  Head Neck Pathol       Date:  2014-12-07

Review 7.  Impact of human papillomavirus on oropharyngeal cancer biology and response to therapy: implications for treatment.

Authors:  Juliana Bonilla-Velez; Edmund A Mroz; Rebecca J Hammon; James W Rocco
Journal:  Otolaryngol Clin North Am       Date:  2013-06-27       Impact factor: 3.346

Review 8.  A river model to map convergent cancer evolution and guide therapy in RCC.

Authors:  Elizabeth Y Wei; James J Hsieh
Journal:  Nat Rev Urol       Date:  2015-11-03       Impact factor: 14.432

Review 9.  Stem cell therapies for the treatment of radiation-induced normal tissue side effects.

Authors:  Marc Benderitter; Fabio Caviggioli; Alain Chapel; Robert P Coppes; Chandan Guha; Marco Klinger; Olivier Malard; Fiona Stewart; Radia Tamarat; Peter van Luijk; Charles L Limoli
Journal:  Antioxid Redox Signal       Date:  2014-02-03       Impact factor: 8.401

Review 10.  Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types.

Authors:  Tara C Gangadhar; April Ks Salama
Journal:  Onco Targets Ther       Date:  2015-04-22       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.